Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Recent Patents on Biotechnology|January 13, 2023
Patent and Marketing Exclusivities 101 for Drug DevelopersBryan Oronsky, Scott Caroen, Franck Brinkhaus, et al.Journal for Immunotherapy of Cancer|June 17, 2024
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believingAnthony Conley, Christopher Larson, Bryan Oronsky, et al.Oncotarget|August 18, 2015
Going viral: a review of replication-selective oncolytic adenovirusesChristopher Larson, Bryan Oronsky, Jan Scicinski, et al.Case Reports in Oncology|April 3, 2023
Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma PatientSantosh Kesari, Jeannie Williams, Erica Burbano, et al.Clinical Colorectal Cancer|December 18, 2022
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal CancerTony R Reid, Nacer Abrouk, Scott Caroen, et al.Clinical and Translational Science|June 29, 2023
Data Management 101 for drug developers: A peek behind the curtainBryan Oronsky, Erica Burbano, Meaghan Stirn, et al.Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.American Journal of Cancer Research|October 13, 2022
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trialsXiaoning Guo, Xiaohui Wang, Sui Shen, et al.Future Oncology (London, England)|August 11, 2022
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumorsSantosh Kesari, Alberto Bessudo, Brian R Gastman, et al.Cancer Gene Therapy|December 25, 2023
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumorsAnthony P Conley, Christina L Roland, Alberto Bessudo, et al.Pageof 2